丹诺医药(苏州)股份有限公司

HPC HOLDINGS

NEXION TECH

ASIA ENERGY LOG

TOUYUN BIOTECH

BOER POWER

KNOWLEDGE ATLAS

WAI CHUN GROUP

VPOWER GROUP

CCOE

<p>36Kr learned that the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice regarding the "full circulation" of Danuo Pharmaceutical (Suzhou) Co., Ltd.'s overseas issuance and listing, as well as its domestic unlisted shares. The company plans to issue no more than 12,498,400 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange. A total of 49 shareholders of the company intend to convert their combined 43,472,926 domestic unlisted shares into overseas listed shares and list them for trading on the Hong Kong Stock Exchange</p>

36Kr

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

亦诺微医药

Guotai CSI Bio-medicine ETF

InnoCare Pharma

China Southern Hang Seng Biotech ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

INNOCARE

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

INNOGEN-B

Danno Pharma's Hong Kong stock IPO and domestic unlisted shares "full circulation" have been filed with the China Securities Regulatory Commission

丹诺医药(苏州)股份有限公司(N25189.HK)

Danno Pharma's Hong Kong stock IPO and domestic unlisted shares "full circulation" have been filed with the China Securities Regulatory Commission